Northern Trust’s Repros Therapeutics Inc. RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-83,753
Closed -$56K 4351
2017
Q4
$56K Buy
83,753
+3,687
+5% +$1.86K ﹤0.01% 4060
2017
Q3
$25K Buy
80,066
+3,879
+5% +$1.36K ﹤0.01% 4138
2017
Q2
$34K Sell
76,187
-623
-0.8% -$453 ﹤0.01% 4127
2017
Q1
$92K Buy
76,810
+4,138
+6% +$5.17K ﹤0.01% 3969
2016
Q4
$96K Buy
72,672
+7,534
+12% +$13.1K ﹤0.01% 3913
2016
Q3
$137K Buy
65,138
+4,833
+8% +$9.56K ﹤0.01% 3824
2016
Q2
$98K Sell
60,305
-5,846
-9% -$11.2K ﹤0.01% 3895
2016
Q1
$92K Sell
66,151
-42,717
-39% -$41.7K ﹤0.01% 3923
2015
Q4
$132K Buy
108,868
+20
+0% +$64 ﹤0.01% 3873
2015
Q3
$809K Sell
108,848
-162,466
-60% -$1.24M ﹤0.01% 3371
2015
Q2
$1.94M Sell
271,314
-23,437
-8% -$183K ﹤0.01% 3074
2015
Q1
$2.53M Buy
294,751
+760
+0.3% +$6.8K ﹤0.01% 2984
2014
Q4
$2.93M Buy
293,991
+16,056
+6% +$137K ﹤0.01% 2846
2014
Q3
$2.75M Sell
277,935
-17,836
-6% -$264K ﹤0.01% 2889
2014
Q2
$5.12M Sell
295,771
-23,522
-7% -$383K ﹤0.01% 2501
2014
Q1
$5.66M Sell
319,293
-21,498
-6% -$416K ﹤0.01% 2474
2013
Q4
$6.24M Buy
340,791
+2,435
+0.7% +$46K ﹤0.01% 2403
2013
Q3
$9.07M Buy
338,356
+66,725
+25% +$1.43M ﹤0.01% 2095
2013
Q2
$5.01M Buy
+271,631
New +$4.8M ﹤0.01% 2418

Northern Trust's RPRX Position: Q1 2018 in Review

Northern Trust sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 83,753 shares — an estimated $56K sold.

Northern Trust first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $9.07M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.

  • Northern Trust reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
  • Northern Trust sold 83,753 Repros Therapeutics Inc. shares in Q1 2018, an estimated $56K.
  • Northern Trust first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
  • Northern Trust's Repros Therapeutics Inc. position peaked at $9.07M in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.

Based on Northern Trust's 13F filing for Q1 2018, filed 9 May 2018.